AlphaQuest LLC Buys New Stake in Integer Holdings Corporation $ITGR

Key Points

• AlphaQuest LLC has acquired 19,542 shares in Integer Holdings Corporation valued at approximately $2.3 million, highlighting ongoing institutional interest in the medical equipment provider.
• Integer Holdings Corporation reported an EPS of $1.55 for the last quarter, missing analysts' expectations slightly, although revenues were up 11.4% year-over-year.
• Institutional investors currently own 99.29% of Integer Holdings, indicating significant confidence from large investors despite recent stock fluctuations.

AlphaQuest LLC acquired a new stake in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,542 shares of the medical equipment provider's stock, valued at approximately $2,306,000. AlphaQuest LLC owned 0.06% of Integer at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ITGR. AdvisorNet Financial Inc bought a new position in shares of Integer in the first quarter worth $28,000. Opal Wealth Advisors LLC purchased a new position in shares of Integer during the first quarter valued at about $28,000. Bessemer Group Inc. increased its position in shares of Integer by 73.1% during the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 125 shares during the period. Sterling Capital Management LLC increased its position in shares of Integer by 472.9% during the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 279 shares during the period. Finally, Headlands Technologies LLC raised its holdings in Integer by 1,234.8% in the first quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock worth $145,000 after buying an additional 1,136 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

Integer Stock Down 0.5%

Shares of NYSE ITGR traded down $0.49 during midday trading on Wednesday, reaching $107.97. 44,598 shares of the company's stock traded hands, compared to its average volume of 474,223. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. The company has a market cap of $3.78 billion, a price-to-earnings ratio of 47.59, a P/E/G ratio of 0.86 and a beta of 1.02. The stock's 50 day simple moving average is $113.36 and its 200-day simple moving average is $118.60. Integer Holdings Corporation has a one year low of $104.93 and a one year high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). The firm had revenue of $476.00 million for the quarter, compared to analysts' expectations of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The company's revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, analysts predict that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling at Integer

In other news, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total value of $1,774,280.82. Following the sale, the director directly owned 18,781 shares of the company's stock, valued at $2,260,856.78. This represents a 43.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the completion of the sale, the director directly owned 22,170 shares in the company, valued at $2,672,815.20. This trade represents a 28.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ITGR. Truist Financial decreased their price target on Integer from $145.00 to $137.00 and set a "buy" rating for the company in a research note on Friday, July 25th. Raymond James Financial cut their price target on Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a report on Friday, July 25th. Citigroup upgraded Integer from a "hold" rating to a "strong-buy" rating and boosted their price objective for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Wells Fargo & Company dropped their price target on Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a research report on Friday, July 25th. Finally, Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a research note on Monday, May 19th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $140.25.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.